MBC101: The HER2-Low Show
Essential Knowledge, Entities of Cancer, MBC Imaging and Profiling, Novel Treatments, MBC Patients, Medical Community, Precision Oncology, MBC Stories, Clinical Research, Challenges and Barriers Our MBClife Essential Knowledge, Entities of Cancer, MBC Imaging and Profiling, Novel Treatments, MBC Patients, Medical Community, Precision Oncology, MBC Stories, Clinical Research, Challenges and Barriers Our MBClife

MBC101: The HER2-Low Show

The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.

Read More
ER Progression and Resistance: Causes, Consequences, and Hope
Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife

ER Progression and Resistance: Causes, Consequences, and Hope

Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.

Read More
Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
Novel Treatments, Medical Community, Challenges and Barriers, MBC Research Funding, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options, Clinical Research Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, MBC Research Funding, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Difficult to Treat, Obstacles to Better Outcomes, Patient Reported Outcomes and Out of the Box Treatment Options, Clinical Research Our MBClife

Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin

The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.

Read More